

# Stephen J Greene

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/10408337/stephen-j-greene-publications-by-year.pdf>

**Version:** 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

168  
papers

5,635  
citations

35  
h-index

71  
g-index

209  
ext. papers

7,966  
ext. citations

7.4  
avg, IF

5.72  
L-index

#	Paper	IF	Citations
168	Trends and characteristics of hospitalizations for heart failure in the United States from 2004 to 2018.. <i>ESC Heart Failure</i> , <b>2022</b> ,	3.7	2
167	Most Common Causes of Hospitalization Associated with Inpatient Mortality in the United States between 2005-2018.. <i>American Journal of the Medical Sciences</i> , <b>2022</b> ,	2.2	
166	Annals for Hospitalists Inpatient Notes - Clinical Pearls-Stopping, Starting, and Optimizing Guideline-Directed Medical Therapy in Patients Hospitalized for Heart Failure With Reduced Ejection Fraction.. <i>Annals of Internal Medicine</i> , <b>2022</b> , 175, HO2-HO3	8	
165	Trends in Characteristics and Outcomes of Peripartum Cardiomyopathy Hospitalizations in the United States Between 2004 and 2018.. <i>American Journal of Cardiology</i> , <b>2022</b> ,	3	1
164	Robustness of outcomes in trials evaluating sodium-glucose co-transporter 2 inhibitors for heart failure.. <i>ESC Heart Failure</i> , <b>2022</b> ,	3.7	1
163	Trends in Characteristics and Outcomes in Primary Heart Failure Hospitalizations Among Older Population in the United States, 2004-2018.. <i>Circulation: Heart Failure</i> , <b>2022</b> , CIRCHEARTFAILURE121008943	7.6	0
162	Efficacy and safety of sodium-glucose cotransporter 2 inhibitors initiation in patients with acute heart failure, with and without type 2 diabetes: a systematic review and meta-analysis.. <i>Cardiovascular Diabetology</i> , <b>2022</b> , 21, 20	8.7	3
161	Trends in hospitalizations for heart failure, acute myocardial infarction, and stroke in the United States from 2004 to 2018. <i>American Heart Journal</i> , <b>2022</b> , 243, 103-109	4.9	7
160	Evaluation of Representation of Women as Authors in Pivotal Trials Supporting US Food and Drug Administration Approval of Novel Cardiovascular Drugs.. <i>JAMA Network Open</i> , <b>2022</b> , 5, e220035	10.4	2
159	Frailty, Guideline-Directed Medical Therapy, and Outcomes in HFREF: From the GUIDE-IT Trial.. <i>JACC: Heart Failure</i> , <b>2022</b> , 10, 266-275	7.9	1
158	Trends in HF Hospitalizations Among Young Adults in the United States From 2004 to 2018.. <i>JACC: Heart Failure</i> , <b>2022</b> , 10, 350-362	7.9	0
157	Titration of medical therapy and clinical outcomes among patients with heart failure with reduced ejection fraction: findings from the HF-ACTION trial. <i>American Heart Journal</i> , <b>2022</b> , 251, 115-115	4.9	0
156	Contemporary Outpatient Management of Patients with Worsening Heart Failure with Reduced Ejection Fraction: Rationale and Design of the CHART-HF Study. <i>American Heart Journal</i> , <b>2022</b> , 251, 127-127	4.9	0
155	Sodium-glucose co-transporter 2 inhibitors as an early, first line therapy in patients with heart failure and reduced ejection fraction. <i>European Journal of Heart Failure</i> , <b>2021</b> ,	12.3	9
154	Factors Associated With Racial and Ethnic Diversity Among Heart Failure Trial Participants: A Systematic Bibliometric Review.. <i>Circulation: Heart Failure</i> , <b>2021</b> , CIRCHEARTFAILURE121008685	7.6	5
153	In-Hospital Initiation of Sodium-Glucose Cotransporter-2 Inhibitors for Heart Failure With Reduced Ejection Fraction. <i>Journal of the American College of Cardiology</i> , <b>2021</b> , 78, 2004-2012	15.1	7
152	Contextualizing Risk Among Patients With Heart Failure. <i>JAMA - Journal of the American Medical Association</i> , <b>2021</b> ,	27.4	2

151	Beta-blocker and ACE-inhibitor dosing as a function of body surface area: From the HF-ACTION trial. <i>American Heart Journal</i> , <b>2021</b> , 233, 1-4	4.9	0
150	Effects of sodium-glucose cotransporter 1 and 2 inhibitors on cardiovascular and kidney outcomes in type 2 diabetes: A meta-analysis update. <i>American Heart Journal</i> , <b>2021</b> , 233, 86-91	4.9	15
149	Prognostic Role of Prior Heart Failure Hospitalization Among Patients Hospitalized for Worsening Chronic Heart Failure. <i>Circulation: Heart Failure</i> , <b>2021</b> , 14, e007871	7.6	4
148	Update on the Impact of Comorbidities on the Efficacy and Safety of Heart Failure Medications. <i>Current Heart Failure Reports</i> , <b>2021</b> , 18, 132-143	2.8	1
147	Meta-Analysis of Efficacy of Sacubitril/Valsartan in Heart Failure With Preserved Ejection Fraction. <i>American Journal of Cardiology</i> , <b>2021</b> , 145, 165-168	3	3
146	Trends in 30- and 90-Day Readmission Rates for Heart Failure. <i>Circulation: Heart Failure</i> , <b>2021</b> , 14, e008335	7.6	15
145	Pragmatic Design of Randomized Clinical Trials for Heart Failure: Rationale and Design of the TRANSFORM-HF Trial. <i>JACC: Heart Failure</i> , <b>2021</b> , 9, 325-335	7.9	6
144	Comparison of New York Heart Association Class and Patient-Reported Outcomes for Heart Failure With Reduced Ejection Fraction. <i>JAMA Cardiology</i> , <b>2021</b> , 6, 522-531	16.2	6
143	Estimated Glomerular Filtration Rate Variability in Patients With Heart Failure and Chronic Kidney Disease. <i>Journal of Cardiac Failure</i> , <b>2021</b> , 27, 1175-1184	3.3	1
142	Sex Differences in Clinical Course and Patient-Reported Outcomes Among Patients Hospitalized for Heart Failure. <i>JACC: Heart Failure</i> , <b>2021</b> , 9, 336-345	7.9	6
141	Drugs of Abuse and Heart Failure. <i>Journal of Cardiac Failure</i> , <b>2021</b> , 27, 1260-1275	3.3	4
140	Simultaneous or Rapid Sequence Initiation of Quadruple Medical Therapy for Heart Failure-Optimizing Therapy With the Need for Speed. <i>JAMA Cardiology</i> , <b>2021</b> , 6, 743-744	16.2	30
139	Trends in Substance Abuse Disorders Among Patients Hospitalized for Heart Failure in the United States. <i>Circulation: Heart Failure</i> , <b>2021</b> , 14, e008147	7.6	0
138	Body surface area and medication dosing in patients with heart failure with reduced ejection fraction. <i>Trends in Cardiovascular Medicine</i> , <b>2021</b> , 31, 111-116	6.9	1
137	Comparison of Dyspnea Measurement Instruments in Acute Heart Failure: The DYPNEA-AHF Pilot Study. <i>Journal of Cardiac Failure</i> , <b>2021</b> , 27, 607-609	3.3	1
136	Temporal trends in risk profiles among patients hospitalized for heart failure. <i>American Heart Journal</i> , <b>2021</b> , 232, 154-163	4.9	3
135	Reporting and interpretation of subgroup analyses in heart failure randomized controlled trials. <i>ESC Heart Failure</i> , <b>2021</b> , 8, 26-36	3.7	2
134	Implications of peripheral oedema in heart failure with preserved ejection fraction: a heart failure network analysis. <i>ESC Heart Failure</i> , <b>2021</b> , 8, 662-669	3.7	2

133	Treatment of HF in an Era of Multiple Therapies: Statement From the HF Collaboratory. <i>JACC: Heart Failure</i> , <b>2021</b> , 9, 1-12	7.9	10
132	Discontinuation and non-publication of heart failure randomized controlled trials: a call to publish all trial results. <i>ESC Heart Failure</i> , <b>2021</b> , 8, 16-25	3.7	1
131	Effect of sodium-glucose cotransporter 2 inhibitors on cardiovascular and kidney outcomes-Systematic review and meta-analysis of randomized placebo-controlled trials. <i>American Heart Journal</i> , <b>2021</b> , 232, 10-22	4.9	31
130	Building a Heart Failure Clinic: A Practical Guide from the Heart Failure Society of America. <i>Journal of Cardiac Failure</i> , <b>2021</b> , 27, 2-19	3.3	5
129	Factors associated with non-use and sub-target dosing of medical therapy for heart failure with reduced ejection fraction. <i>Heart Failure Reviews</i> , <b>2021</b> , 1	5	1
128	Kidney Function and Outcomes in Patients Hospitalized With Heart Failure. <i>Journal of the American College of Cardiology</i> , <b>2021</b> , 78, 330-343	15.1	14
127	Sacubitril/Valsartan Initiation and Postdischarge Adherence Among Patients Hospitalized for Heart Failure. <i>Journal of Cardiac Failure</i> , <b>2021</b> , 27, 826-836	3.3	4
126	Effect of patient-centered transitional care services on patient-reported outcomes in heart failure: sex-specific analysis of the PACT-HF randomized controlled trial. <i>European Journal of Heart Failure</i> , <b>2021</b> , 23, 1488-1498	12.3	7
125	Participation in a Heart Failure Clinical Trial: Perspectives and Opportunities From the VICTORIA Trial and VICTORIA Simultaneous Registry. <i>Circulation: Heart Failure</i> , <b>2021</b> , 14, e008242	7.6	2
124	Clinical Effectiveness of Sacubitril/Valsartan Among Patients Hospitalized for Heart Failure With Reduced Ejection Fraction. <i>Journal of the American Heart Association</i> , <b>2021</b> , 10, e021459	6	2
123	Sex-Differences in Cause of Death for Patients Hospitalized for Heart Failure With Reduced Versus Preserved Ejection Fraction (from the ASCEND-HF Trial). <i>American Journal of Cardiology</i> , <b>2021</b> , 154, 123-126	3.26	1
122	Sacubitril/Valsartan Adherence and Postdischarge Outcomes Among Patients Hospitalized for Heart Failure With Reduced Ejection Fraction. <i>JACC: Heart Failure</i> , <b>2021</b> , 9, 876-886	7.9	5
121	Potential Implications of Expanded US Food and Drug Administration Labeling for Sacubitril/Valsartan in the US. <i>JAMA Cardiology</i> , <b>2021</b> ,	16.2	4
120	Physical Functioning in Heart Failure With Preserved Ejection Fraction. <i>Journal of Cardiac Failure</i> , <b>2021</b> , 27, 1002-1016	3.3	0
119	Clinical Outcomes With Metformin and Sulfonylurea Therapies Among Patients With Heart Failure and Diabetes. <i>JACC: Heart Failure</i> , <b>2021</b> ,	7.9	4
118	Effects of Liraglutide on Worsening Renal Function Among Patients With Heart Failure With Reduced Ejection Fraction: Insights From the FIGHT Trial. <i>Circulation: Heart Failure</i> , <b>2020</b> , 13, e006758	7.6	6
117	Risk Profiles in Heart Failure: Baseline, Residual, Worsening, and Advanced Heart Failure Risk. <i>Circulation: Heart Failure</i> , <b>2020</b> , 13, e007132	7.6	11
116	Sacubitril/Valsartan in Advanced Heart Failure With Reduced Ejection Fraction: Rationale and Design of the LIFE Trial. <i>JACC: Heart Failure</i> , <b>2020</b> , 8, 789-799	7.9	19

115	A Meta-analysis of the Relationship Between Renin-Angiotensin-Aldosterone System Inhibitors and COVID-19. <i>American Journal of Cardiology</i> , <b>2020</b> , 130, 159-161	3	14
114	Enrollment of Older Patients, Women, and Racial/Ethnic Minority Groups in Contemporary Acute Coronary Syndrome Clinical Trials: A Systematic Review. <i>JAMA Cardiology</i> , <b>2020</b> , 5, 714-722	16.2	29
113	Contemporary Treatment Patterns and Clinical Outcomes of Comorbid Diabetes Mellitus and HFrEF: The CHAMP-HF Registry. <i>JACC: Heart Failure</i> , <b>2020</b> , 8, 469-480	7.9	16
112	Patient Perceptions and Familiarity With Medical Therapy for Heart Failure. <i>JAMA Cardiology</i> , <b>2020</b> , 5, 292-299	16.2	8
111	Diastolic Dysfunction in Patients With Human Immunodeficiency Virus Receiving Antiretroviral Therapy: Results From the CHART Study. <i>Journal of Cardiac Failure</i> , <b>2020</b> , 26, 371-380	3.3	10
110	Are existing and emerging biomarkers associated with cardiorespiratory fitness in patients with chronic heart failure?. <i>American Heart Journal</i> , <b>2020</b> , 220, 97-107	4.9	3
109	Post-discharge haemodilution, congestion, and clinical outcomes among patients hospitalized for heart failure with reduced ejection fraction: results from the EVEREST trial. <i>European Journal of Heart Failure</i> , <b>2020</b> , 22, 164-167	12.3	2
108	Tobacco smoking in patients with heart failure and coronary artery disease: A 20-year experience at Duke University Medical Center. <i>American Heart Journal</i> , <b>2020</b> , 230, 25-34	4.9	3
107	In-hospital outcomes after bariatric surgery in patients with heart failure. <i>American Heart Journal</i> , <b>2020</b> , 230, 59-62	4.9	2
106	Representation of Women Authors in International Heart Failure Guidelines and Contemporary Clinical Trials. <i>Circulation: Heart Failure</i> , <b>2020</b> , 13, e006605	7.6	27
105	In-Hospital Therapy for Heart Failure With Reduced Ejection Fraction in the United States. <i>JACC: Heart Failure</i> , <b>2020</b> , 8, 943-953	7.9	10
104	Trends in prevalence of comorbidities in heart failure clinical trials. <i>European Journal of Heart Failure</i> , <b>2020</b> , 22, 1032-1042	12.3	18
103	Applicability of US Food and Drug Administration Labeling for Dapagliflozin to Patients With Heart Failure With Reduced Ejection Fraction in US Clinical Practice: The Get With the Guidelines-Heart Failure (GWTG-HF) Registry. <i>JAMA Cardiology</i> , <b>2020</b> ,	16.2	8
102	Efficacy and safety of SGLT2 inhibitors in heart failure: systematic review and meta-analysis. <i>ESC Heart Failure</i> , <b>2020</b> , 7, 3298-3309	3.7	26
101	Trends in prevalence of comorbidities in heart failure clinical trials <b>2020</b> , 22, 1032		1
100	Haemoconcentration during treatment of acute heart failure with cardiorenal syndrome: from the CARRESS-HF trial. <i>European Journal of Heart Failure</i> , <b>2019</b> , 21, 1472-1476	12.3	1
99	Titration of Medical Therapy for Heart Failure With Reduced Ejection Fraction. <i>Journal of the American College of Cardiology</i> , <b>2019</b> , 73, 2365-2383	15.1	147
98	Outpatient Intravenous Diuretic Therapy for Heart Failure in the United States. <i>Journal of the American College of Cardiology</i> , <b>2019</b> , 73, 1101-1103	15.1	11

97	Do Women and Men Respond Similarly to Therapies in Contemporary Heart Failure Clinical Trials? <i>JACC: Heart Failure</i> , <b>2019</b> , 7, 267-271	7.9	9
96	Spirolactone in Acute Heart Failure Patients With Renal Dysfunction and Risk Factors for Diuretic Resistance: From the ATHENA-HF Trial. <i>Canadian Journal of Cardiology</i> , <b>2019</b> , 35, 1097-1105	3.8	14
95	Representativeness of a Heart Failure Trial by Race and Sex: Results From ASCEND-HF and GWTG-HF. <i>JACC: Heart Failure</i> , <b>2019</b> , 7, 980-992	7.9	11
94	Reply: Titration of Guideline-Directed Medical Therapy Improves Patient-Centered Outcomes in Heart Failure With Reduced Ejection Fraction. <i>Journal of the American College of Cardiology</i> , <b>2019</b> , 74, 1426-1427	15.1	2
93	Health-Related Quality of Life in Comorbid Heart Failure With Reduced Ejection Fraction and Diabetes Mellitus. <i>Journal of the American College of Cardiology</i> , <b>2019</b> , 74, 3176-3178	15.1	3
92	Identifying responders to oral iron supplementation in heart failure with a reduced ejection fraction: a post-hoc analysis of the IRONOUT-HF trial. <i>Journal of Cardiovascular Medicine</i> , <b>2019</b> , 20, 223-228	1.9	9
91	Initiation, Continuation, Switching, and Withdrawal of Heart Failure Medical Therapies During Hospitalization. <i>JACC: Heart Failure</i> , <b>2019</b> , 7, 1-12	7.9	51
90	History of Atrial Fibrillation and Trajectory of Decongestion in Acute Heart Failure. <i>JACC: Heart Failure</i> , <b>2019</b> , 7, 47-55	7.9	6
89	Medication dosing for heart failure with reduced ejection fraction - opportunities and challenges. <i>European Journal of Heart Failure</i> , <b>2019</b> , 21, 286-296	12.3	32
88	Prevalent digoxin use and subsequent risk of death or hospitalization in ambulatory heart failure patients with a reduced ejection fraction-Findings from the Heart Failure: A Controlled Trial Investigating Outcomes of Exercise Training (HF-ACTION) randomized controlled trial. <i>American Heart Journal</i> , <b>2018</b> , 199, 97-104	4.9	4
87	The role of angiotensin receptor-nepriylisin inhibitors in cardiovascular disease-existing evidence, knowledge gaps, and future directions. <i>European Journal of Heart Failure</i> , <b>2018</b> , 20, 963-972	12.3	27
86	Outpatient Worsening Heart Failure as a Target for Therapy: A Review. <i>JAMA Cardiology</i> , <b>2018</b> , 3, 252-256	6.2	43
85	Evolving Landscape of Clinical Trials in Heart Failure: Patient Populations, Endpoint Selection, and Regions of Enrollment. <i>Current Heart Failure Reports</i> , <b>2018</b> , 15, 10-16	2.8	5
84	Globalization of heart failure clinical trials: a systematic review of 305 trials conducted over 16 years. <i>European Journal of Heart Failure</i> , <b>2018</b> , 20, 1068-1071	12.3	11
83	Is Time of the Essence? The Impact of Time of Hospital Presentation in Acute Heart Failure: Insights From ASCEND-HF Trial. <i>JACC: Heart Failure</i> , <b>2018</b> , 6, 298-307	7.9	2
82	Expanded algorithm for managing patients with acute decompensated heart failure. <i>Heart Failure Reviews</i> , <b>2018</b> , 23, 597-607	5	4
81	Prevalent and Incident Heart Failure in Cardiovascular Outcome Trials of Patients With Type 2 Diabetes. <i>Journal of the American College of Cardiology</i> , <b>2018</b> , 71, 1379-1390	15.1	43
80	Bulletproof heart: Gunshot wound to the ventricular septum without pericardial effusion or hemodynamic collapse. <i>Canadian Journal of Emergency Medicine</i> , <b>2018</b> , 20, S40	0.6	

79	Pre-discharge and early post-discharge troponin elevation among patients hospitalized for heart failure with reduced ejection fraction: findings from the ASTRONAUT trial. <i>European Journal of Heart Failure</i> , <b>2018</b> , 20, 281-291	12.3	17
78	Worsening renal function during decongestion among patients hospitalized for heart failure: Findings from the Evaluation Study of Congestive Heart Failure and Pulmonary Artery Catheterization Effectiveness (ESCAPE) trial. <i>American Heart Journal</i> , <b>2018</b> , 204, 163-173	4.9	21
77	Medical Therapy for Heart Failure With Reduced Ejection Fraction: The CHAMP-HF Registry. <i>Journal of the American College of Cardiology</i> , <b>2018</b> , 72, 351-366	15.1	333
76	Design Elements and Enrollment Patterns of Contemporary Trials in Heart Failure With Preserved Ejection Fraction: A Systematic Review. <i>JACC: Heart Failure</i> , <b>2018</b> , 6, 714-717	7.9	3
75	Sudden Death After Hospitalization for Heart Failure With Reduced Ejection Fraction (from the EVEREST Trial). <i>American Journal of Cardiology</i> , <b>2018</b> , 122, 255-260	3	4
74	Enrollment of Older Patients, Women, and Racial and Ethnic Minorities in Contemporary Heart Failure Clinical Trials: A Systematic Review. <i>JAMA Cardiology</i> , <b>2018</b> , 3, 1011-1019	16.2	79
73	Home-Time After Discharge Among Patients Hospitalized With Heart Failure. <i>Journal of the American College of Cardiology</i> , <b>2018</b> , 71, 2643-2652	15.1	43
72	Prevalence and prognostic impact of non-cardiac co-morbidities in heart failure outpatients with preserved and reduced ejection fraction: a community-based study. <i>European Journal of Heart Failure</i> , <b>2018</b> , 20, 1257-1266	12.3	76
71	Aetiology, timing and clinical predictors of early vs. late readmission following index hospitalization for acute heart failure: insights from ASCEND-HF. <i>European Journal of Heart Failure</i> , <b>2018</b> , 20, 304-314	12.3	30
70	Plasma renin activity, response to aliskiren, and clinical outcomes in patients hospitalized for heart failure: the ASTRONAUT trial. <i>European Journal of Heart Failure</i> , <b>2018</b> , 20, 677-686	12.3	13
69	Relationship between timing of trial randomization, protocol completion, and clinical outcomes among patients hospitalized for heart failure: from the ASTRONAUT trial. <i>European Journal of Heart Failure</i> , <b>2018</b> , 20, 1760-1763	12.3	2
68	Relationship Between Enrolling Country Income Level and Patient Profile, Protocol Completion, and Trial End Points. <i>Circulation: Cardiovascular Quality and Outcomes</i> , <b>2018</b> , 11, e004783	5.8	7
67	Reassessing the Role of Surrogate End Points in Drug Development for Heart Failure. <i>Circulation</i> , <b>2018</b> , 138, 1039-1053	16.7	13
66	Nomenclature in heart failure: a call for objective, reproducible, and biologically-driven terminology. <i>European Journal of Heart Failure</i> , <b>2018</b> , 20, 1379-1381	12.3	5
65	Rationale and design of a randomized controlled trial of allogeneic mesenchymal stem cells in patients with nonischemic cardiomyopathy. <i>Journal of Cardiovascular Medicine</i> , <b>2017</b> , 18, 283-290	1.9	4
64	Association between funding sources and the scope and outcomes of cardiovascular clinical trials: A systematic review. <i>International Journal of Cardiology</i> , <b>2017</b> , 230, 301-303	3.2	5
63	Trajectory of Congestion Metrics by Ejection Fraction in Patients With Acute Heart Failure (from the Heart Failure Network). <i>American Journal of Cardiology</i> , <b>2017</b> , 120, 98-105	3	9
62	Influence of atrial fibrillation on post-discharge natriuretic peptide trajectory and clinical outcomes among patients hospitalized for heart failure: insights from the ASTRONAUT trial. <i>European Journal of Heart Failure</i> , <b>2017</b> , 19, 552-562	12.3	19

61	Hospitalization for Recently Diagnosed Versus Worsening Chronic Heart Failure: From the ASCEND-HF Trial. <i>Journal of the American College of Cardiology</i> , <b>2017</b> , 69, 3029-3039	15.1	41
60	Aerobic exercise training and general health status in ambulatory heart failure patients with a reduced ejection fraction-Findings from the Heart Failure and A Controlled Trial Investigating Outcomes of Exercise Training (HF-ACTION)trial. <i>American Heart Journal</i> , <b>2017</b> , 186, 130-138	4.9	21
59	Drug Development for Heart Failure With Preserved Ejection Fraction: What Pieces Are Missing From the Puzzle?. <i>Canadian Journal of Cardiology</i> , <b>2017</b> , 33, 768-776	3.8	8
58	Expert consensus document: Mitochondrial function as a therapeutic target in heart failure. <i>Nature Reviews Cardiology</i> , <b>2017</b> , 14, 238-250	14.8	322
57	Body Weight Change During and After Hospitalization for Acute Heart Failure: Patient Characteristics, Markers of Congestion, and Outcomes: Findings From the ASCEND-HF Trial. <i>JACC: Heart Failure</i> , <b>2017</b> , 5, 1-13	7.9	58
56	Renin-angiotensin blockade in heart failure with preserved ejection fraction: a systematic review and meta-analysis. <i>ESC Heart Failure</i> , <b>2017</b> , 4, 402-408	3.7	32
55	Strategy to identify subjects with diabetes mellitus more suitable for selective echocardiographic screening: The DAVID-Berg study. <i>International Journal of Cardiology</i> , <b>2017</b> , 248, 414-420	3.2	4
54	Dose of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers and Outcomes in Heart Failure: A Meta-Analysis. <i>Circulation: Heart Failure</i> , <b>2017</b> , 10,	7.6	26
53	Intravenous Allogeneic Mesenchymal Stem Cells for Nonischemic Cardiomyopathy: Safety and Efficacy Results of a Phase II-A Randomized Trial. <i>Circulation Research</i> , <b>2017</b> , 120, 332-340	15.7	105
52	Predictors of Post-discharge Mortality Among Patients Hospitalized for Acute Heart Failure. <i>Cardiac Failure Review</i> , <b>2017</b> , 3, 122-129	4.2	18
51	Serum insulin-like growth factor-1 and its binding protein-7: potential novel biomarkers for heart failure with preserved ejection fraction. <i>BMC Cardiovascular Disorders</i> , <b>2016</b> , 16, 199	2.3	25
50	Heart Failure Clinical Trials in East and Southeast Asia: Understanding the Importance and Defining the Next Steps. <i>JACC: Heart Failure</i> , <b>2016</b> , 4, 419-27	7.9	34
49	Serum Osmolality and Postdischarge Outcomes After Hospitalization for Heart Failure. <i>American Journal of Cardiology</i> , <b>2016</b> , 117, 1144-50	3	16
48	Partial adenosine A1 receptor agonism: a potential new therapeutic strategy for heart failure. <i>Heart Failure Reviews</i> , <b>2016</b> , 21, 95-102	5	44
47	Trends in Heart Failure Clinical Trials From 2001-2012. <i>Journal of Cardiac Failure</i> , <b>2016</b> , 22, 171-9	3.3	13
46	Temporal Changes in Postdischarge Mortality Risk After Hospitalization for Heart Failure (from the EVEREST Trial). <i>American Journal of Cardiology</i> , <b>2016</b> , 117, 611-616	3	11
45	Effects of Polyunsaturated Fatty Acid Treatment on Postdischarge Outcomes After Acute Myocardial Infarction. <i>American Journal of Cardiology</i> , <b>2016</b> , 117, 340-6	3	12
44	Natriuretic peptide-guided management in heart failure. <i>Journal of Cardiovascular Medicine</i> , <b>2016</b> , 17, 556-68	1.9	21



43	The clinical course of health status and association with outcomes in patients hospitalized for heart failure: insights from ASCEND-HF. <i>European Journal of Heart Failure</i> , <b>2016</b> , 18, 306-13	12.3	26
42	Influence of Clinical Trial Site Enrollment on Patient Characteristics, Protocol Completion, and End Points: Insights From the ASCEND-HF Trial (Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure). <i>Circulation: Heart Failure</i> , <b>2016</b> , 9,	7.6	10
41	Changes in Dyspnea Status During Hospitalization and Postdischarge Health-Related Quality of Life in Patients Hospitalized for Heart Failure: Findings From the EVEREST Trial. <i>Circulation: Heart Failure</i> , <b>2016</b> , 9,	7.6	14
40	Site selection for heart failure clinical trials in the USA. <i>Heart Failure Reviews</i> , <b>2015</b> , 20, 375-83	5	9
39	Combination decongestion therapy in hospitalized heart failure: loop diuretics, mineralocorticoid receptor antagonists and vasopressin antagonists. <i>Expert Review of Cardiovascular Therapy</i> , <b>2015</b> , 13, 799-809	2.5	10
38	The potential role of natriuretic peptide-guided management for patients hospitalized for heart failure. <i>Journal of Cardiac Failure</i> , <b>2015</b> , 21, 233-9	3.3	13
37	Reply: considerations for drug development for heart failure. <i>Journal of the American College of Cardiology</i> , <b>2015</b> , 65, 1061-2	15.1	2
36	Clinical trials in hospitalized heart failure patients: targeting interventions to optimal phenotypic subpopulations. <i>Heart Failure Reviews</i> , <b>2015</b> , 20, 393-400	5	3
35	Mechanisms Contributing to the Progression of Ischemic and Nonischemic Dilated Cardiomyopathy: Possible Modulating Effects of Paracrine Activities of Stem Cells. <i>Journal of the American College of Cardiology</i> , <b>2015</b> , 66, 2038-2047	15.1	40
34	Hospitalized Heart Failure in the United States: Lessons Learned from Clinical Trial Populations. <i>Heart Failure Clinics</i> , <b>2015</b> , 11, 591-601	3.3	2
33	Effect of Vericiguat, a Soluble Guanylate Cyclase Stimulator, on Natriuretic Peptide Levels in Patients With Worsening Chronic Heart Failure and Reduced Ejection Fraction: The SOCRATES-REDUCED Randomized Trial. <i>JAMA - Journal of the American Medical Association</i> , <b>2015</b> , 314, 2251-62	27.4	188
32	Global variation in clinical profile, management, and post-discharge outcomes among patients hospitalized for worsening chronic heart failure: findings from the ASTRONAUT trial. <i>European Journal of Heart Failure</i> , <b>2015</b> , 17, 591-600	12.3	52
31	In-hospital worsening heart failure. <i>European Journal of Heart Failure</i> , <b>2015</b> , 17, 1104-13	12.3	43
30	Length of hospital stay and 30-day readmission following heart failure hospitalization: insights from the EVEREST trial. <i>European Journal of Heart Failure</i> , <b>2015</b> , 17, 1022-31	12.3	40
29	Contemporary cardiovascular device clinical trials (trends and patterns 2001 to 2012). <i>American Journal of Cardiology</i> , <b>2015</b> , 116, 307-12	3	2
28	Population risk prediction models for incident heart failure: a systematic review. <i>Circulation: Heart Failure</i> , <b>2015</b> , 8, 438-47	7.6	40
27	Identifying Barriers and Practical Solutions to Conducting Site-Based Research in North America: Exploring Acute Heart Failure Trials As a Case Study. <i>Heart Failure Clinics</i> , <b>2015</b> , 11, 581-9	3.3	4
26	The vulnerable phase after hospitalization for heart failure. <i>Nature Reviews Cardiology</i> , <b>2015</b> , 12, 220-9	14.8	129

25	Impact of diabetes on epidemiology, treatment, and outcomes of patients with heart failure. <i>JACC: Heart Failure</i> , <b>2015</b> , 3, 136-45	7.9	190
24	Clinical profile and prognostic significance of natriuretic peptide trajectory following hospitalization for worsening chronic heart failure: findings from the ASTRONAUT trial. <i>European Journal of Heart Failure</i> , <b>2015</b> , 17, 98-108	12.3	23
23	The global health and economic burden of hospitalizations for heart failure: lessons learned from hospitalized heart failure registries. <i>Journal of the American College of Cardiology</i> , <b>2014</b> , 63, 1123-1133	15.1	1160
22	Relation of serum uric acid levels and outcomes among patients hospitalized for worsening heart failure with reduced ejection fraction (from the efficacy of vasopressin antagonism in heart failure outcome study with tolvaptan trial). <i>American Journal of Cardiology</i> , <b>2014</b> , 114, 1713-21	3	35
21	Clinical profile and prognostic value of anemia at the time of admission and discharge among patients hospitalized for heart failure with reduced ejection fraction: findings from the EVEREST trial. <i>Circulation: Heart Failure</i> , <b>2014</b> , 7, 401-8	7.6	27
20	Mineralocorticoid receptor antagonist use in hospitalized patients with heart failure, reduced ejection fraction, and diabetes mellitus (from the EVEREST Trial). <i>American Journal of Cardiology</i> , <b>2014</b> , 114, 743-50	3	8
19	Designing effective drug and device development programs for hospitalized heart failure: a proposal for pretrial registries. <i>American Heart Journal</i> , <b>2014</b> , 168, 142-9	4.9	25
18	Site selection in global clinical trials in patients hospitalized for heart failure: perceived problems and potential solutions. <i>Heart Failure Reviews</i> , <b>2014</b> , 19, 135-52	5	39
17	Hemoconcentration-guided diuresis in heart failure. <i>American Journal of Medicine</i> , <b>2014</b> , 127, 1154-9	2.4	32
16	Dual antiplatelet therapy after stent implantation. <i>JAMA - Journal of the American Medical Association</i> , <b>2014</b> , 311, 1446	27.4	1
15	Influence of chronic kidney disease on warfarin therapy for atrial fibrillation. <i>JAMA - Journal of the American Medical Association</i> , <b>2014</b> , 311, 2541-2	27.4	
14	Coronary artery disease in patients with heart failure: incidental, coincidental, or a target for therapy?. <i>American Journal of Medicine</i> , <b>2014</b> , 127, 574-8	2.4	2
13	Haemodynamic effects, safety, and pharmacokinetics of human stresscopin in heart failure with reduced ejection fraction. <i>European Journal of Heart Failure</i> , <b>2013</b> , 15, 679-89	12.3	26
12	The prognostic significance of heart rate in patients hospitalized for heart failure with reduced ejection fraction in sinus rhythm: insights from the EVEREST (Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study With Tolvaptan) trial. <i>JACC: Heart Failure</i> , <b>2013</b> , 1, 488-96	7.9	49
11	Clinical profile and prognostic value of low systolic blood pressure in patients hospitalized for heart failure with reduced ejection fraction: insights from the Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study with Tolvaptan (EVEREST) trial. <i>American Heart Journal</i> , <b>2013</b> , 165, 216-25	4.9	66
10	Prognostic significance of serum total cholesterol and triglyceride levels in patients hospitalized for heart failure with reduced ejection fraction (from the EVEREST Trial). <i>American Journal of Cardiology</i> , <b>2013</b> , 111, 574-81	3	40
9	The disconnect between phase II and phase III trials of drugs for heart failure. <i>Nature Reviews Cardiology</i> , <b>2013</b> , 10, 85-97	14.8	61
8	Effect of aliskiren on postdischarge mortality and heart failure readmissions among patients hospitalized for heart failure: the ASTRONAUT randomized trial. <i>JAMA - Journal of the American Medical Association</i> , <b>2013</b> , 309, 1125-35	27.4	248

7	Soluble guanylate cyclase: a potential therapeutic target for heart failure. <i>Heart Failure Reviews</i> , <b>2013</b> , 18, 123-34	5	92
6	Effect of aliskiren on post-discharge outcomes among diabetic and non-diabetic patients hospitalized for heart failure: insights from the ASTRONAUT trial. <i>European Heart Journal</i> , <b>2013</b> , 34, 3117-27	9.5	47
5	The cGMP signaling pathway as a therapeutic target in heart failure with preserved ejection fraction. <i>Journal of the American Heart Association</i> , <b>2013</b> , 2, e000536	6	82
4	Haemoconcentration, renal function, and post-discharge outcomes among patients hospitalized for heart failure with reduced ejection fraction: insights from the EVEREST trial. <i>European Journal of Heart Failure</i> , <b>2013</b> , 15, 1401-11	12.3	100
3	Effect of oral digoxin in high-risk heart failure patients: a pre-specified subgroup analysis of the DIG trial. <i>European Journal of Heart Failure</i> , <b>2013</b> , 15, 551-9	12.3	54
2	Prognostic value of monocyte count in patients hospitalized for heart failure with reduced ejection fraction (from the EVEREST Trial). <i>American Journal of Cardiology</i> , <b>2012</b> , 110, 1657-62	3	9
1	Cinaciguat, a soluble guanylate cyclase activator: results from the randomized, controlled, phase IIb COMPOSE programme in acute heart failure syndromes. <i>European Journal of Heart Failure</i> , <b>2012</b> , 14, 1056-66	12.3	88